BCL6 and diffuse large B-cell lymphoma: First, we adapted BCL6 specific inhibitor (compound 79-6) conditions to PMBL cellular model and established IC-50 value (250μM) (data not shown), which was the same as used for treatment of primary DLBCL tumors [15].